Management of Critically Low Hematocrit

Initial Assessment and Management

For a critically low hematocrit of 20.8%, immediate evaluation for signs of hemodynamic compromise, including tachycardia, hypotension, altered mental status, and tissue hypoperfusion is required 1
Patients with critically low hematocrit should be assessed for symptoms of anemia such as fatigue, weakness, dizziness, shortness of breath, and chest pain 2
Evaluation for active bleeding which may require more aggressive transfusion and hemostatic interventions is necessary 3
Underlying causes of severe anemia that may need specific treatment beyond transfusion should be considered 4

The American College of Critical Care Medicine recommends a restrictive transfusion strategy with target hemoglobin of 7-8 g/dL (hematocrit 21-24%) for stable, non-bleeding patients 1, 2
Single-unit RBC transfusions followed by clinical reassessment is preferred over multiple units 2
A higher transfusion threshold with target hemoglobin of 8-10 g/dL (hematocrit 24-30%) may be considered for patients with acute coronary syndrome 2, 5
A retrospective study of patients with acute MI showed that blood transfusion was associated with reduced 30-day mortality when hematocrit was in categories ranging from 5% to 24% (adjusted OR 0.22; 95% CI, 0.11–0.45) 1

Anemia contributes to coagulopathy through multiple mechanisms, including reduced platelet adhesion and aggregation, impaired mechanical and biochemical functions of red blood cells in the coagulation process, and restricted platelet aggregation similar to having only 20,000 platelets/mL at a hematocrit of 20% 4

Monitoring of vital signs before, during, and after transfusion is necessary 1
Assessment for transfusion reactions including fever, urticaria, respiratory distress, or hypotension is required 1
Obtaining post-transfusion hematocrit/hemoglobin to evaluate response is necessary 1
Reassessment of the need for additional transfusions based on clinical response and post-transfusion hematocrit is recommended 2

Blood transfusions carry risks including transfusion reactions, transfusion-related acute lung injury (TRALI), volume overload, infectious disease transmission, and immunomodulation 1, 4